SNCA
If any of the terms on this page are unclear or you want to learn more about them click here!
SNCA is one of the foundational Parkinson’s genes because it encodes alpha-synuclein, the protein that aggregates to form Lewy bodies. Rare pathogenic SNCA variants and gene multiplications can cause autosomal dominant Parkinson’s disease, and SNCA biology is also deeply relevant to more common sporadic PD.
Normal function
Alpha-synuclein is a small protein found especially at the synapses of neurons. It is thought to help regulate the formation of synaptic vesicles (membrane bound sacs containing molecules) and neurotransmitter release. In healthy cells, alpha-synuclein is soluble and functionally integrated into synaptic signaling.
Mutation and effect
Disease-causing SNCA changes include missense mutations, where a protein is made differently, and gene duplications or triplications. These can increase alpha-synuclein levels or alter its behavior in ways that make it more prone to misfolding and aggregation. Because of this, SNCA is unusual in showing that both protein structure and protein dosage can drive disease.
Key mechanisms involved
The key mechanisms include protein misfolding and aggregation, disrupted synaptic vesicle trafficking, and impaired autophagy-lysosome function. When there is too much alpha-synuclein or it is mutated, it aggregates which also clogs the cell’s waste disposal system (lysosome). Further, given its role in the synapse, it can prevent affected neurons from firing properly. Downstream of this is mitochondrial and inflammatory stress. SNCA sits near the center of the protein aggregation story in Parkinson’s disease because alpha-synuclein buildup is both a pathological hallmark and a likely driver of dysfunction.
Implications for treatment
SNCA-related Parkinson’s can resemble typical PD, but some forms, especially gene multiplications, are associated with earlier onset and more severe disease, sometimes including prominent cognitive or psychiatric features. It also maps especially well onto classic Lewy body biology, making it one of the most pathologically defining PD genes.
Research focus
Research is focused on identifying which alpha-synuclein species are most toxic, how pathology spreads through neural systems, and whether lowering alpha-synuclein can safely alter disease course. SNCA is also central to biomarker development because it links genetics, pathology, and therapeutic targeting so directly.
Inheritance
SNCA is a rare cause of Parkinson's, caused either by a typo in the gene or by having extra copies of the whole gene. Extra copies show up in under 1% of Parkinson's cases. The mutation is dominant, so one change is enough to increase odds of disease, and kids where one parent is a carrier face 50/50 odds of inheriting a mutation. People with an extra gene copy don't always get sick, while the rarer typo-versions tend to cause disease in nearly everyone who has them.
Sources
- Singleton, A. B., Farrer, M., Johnson, J., et al. (2003). α-Synuclein locus triplication causes Parkinson’s disease.
- Polymeropoulos, M. H., Lavedan, C., Leroy, E., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease.
- Morris, H., & Lim, S.-Y. (2025). Monogenic Parkinson Disease Overview. In Adam, M. P., Bick, S., Mirzaa, G. M., et al.
- Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., et al. (1997). Alpha-synuclein in Lewy bodies.